Global Acute Agitation and Aggression Treatment market is expected to witness a CAGR of 4.9% during the forecast period. Certain factors that are driving the market growth include rise in burden of mental illness and increase in agitation in patients, increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatment for agitation.
According to the statistics provided by the Mental Health Foundation in 2018, mental health problems are one of the primary causes of rising medical concerns. In addition, according to the United States Census Bureau’s Statistics, as of 2017, the total number of people aged 65 and older exceeds 50 million, and between 2020-2030, the number of elderly population is projected to increase by almost 18 million. Although much smaller in the total size, the number of people aged between 85 years and older is expected to be more than tripled, from an estimated 6 million in 2017, to nearly 20 million by 2060. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the elderly population.
Key Market Trends
Anti-psychotics is Expected to Hold Significant Market Share in the Drug Class Segment
The typical antipsychotics cause sedation, given a high enough dose. Haloperidol, a high potency butyrophenone, has been frequently used as an intramuscular as-needed medication for agitation and aggressive behavior in an emergency department setting for a wide variety of patients. Droperidol, another antipsychotic in the butyrophenone class, is not approved by the US Food and Drug Administration for psychiatric conditions but has been used for sedating agitated patients in an emergency room setting.
Moreover, robust development pipeline coupled with the activity of the manufacturers in launch and collaborations projected to boost the segment growth. For Instance, in May 2017, Otsuka and Lundbeck announce results of brexpiprazole on symptoms of agitation related to Alzheimer’s-type dementia. Furthermore, the growing burden of risk factors fr agitation and aggression such as neurological disorders projected to bolster the market growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
As per the Mental Health America, more than 44 million American adults have a mental health condition (2017). The most commonly reported agents are benzodiazepines, followed by butyrophenone antipsychotics (e.g., haloperidol, droperidol) as reported by directors of emergency medicine residencies and pediatric emergency medicine fellowships in the United States. Moreover, within the United States, approximately 5.7 million people are living with dementia (Alzheimer’s Association, 2018). All these factors are expected to drive the market growth in the region.
The global acute agitation and aggression treatment market is moderately competitive and consists of a few major players. Companies like Eli Lilly and Company, Pfizer, Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Bristol-Myers Squibb, among others, hold the substantial market share in the Acute Agitation and Aggression Treatment market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support